160 related articles for article (PubMed ID: 23270929)
1. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer.
Damiano JS; Rendahl KG; Karim C; Embry MG; Ghoddusi M; Holash J; Fanidi A; Abrams TJ; Abraham JA
Mol Cancer Ther; 2013 Mar; 12(3):295-305. PubMed ID: 23270929
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.
Agarwal N; Machiels JP; Suárez C; Lewis N; Higgins M; Wisinski K; Awada A; Maur M; Stein M; Hwang A; Mosher R; Wasserman E; Wu G; Zhang H; Zieba R; Elmeliegy M
Oncologist; 2016 May; 21(5):535-6. PubMed ID: 27091421
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers.
Kelly MP; Hickey C; Makonnen S; Coetzee S; Jalal S; Wang Y; Delfino F; Shan J; Potocky TB; Chatterjee I; Andreev J; Kunz A; D'Souza C; Giurleo JT; Nittoli T; Trail PA; Thurston G; Kirshner JR
Mol Cancer Ther; 2017 Jul; 16(7):1299-1311. PubMed ID: 28377489
[TBL] [Abstract][Full Text] [Related]
4. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer.
Damiano JS; Wasserman E
Clin Cancer Res; 2013 Apr; 19(7):1644-50. PubMed ID: 23515410
[TBL] [Abstract][Full Text] [Related]
6. Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies.
Standing D; Dandawate P; Anant S
Front Endocrinol (Lausanne); 2022; 13():1112987. PubMed ID: 36714582
[TBL] [Abstract][Full Text] [Related]
7. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract][Full Text] [Related]
8. Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer.
Minami H; Ando Y; Tamura K; Tajima T; Isaacs R
Anticancer Res; 2020 Sep; 40(9):5229-5235. PubMed ID: 32878811
[TBL] [Abstract][Full Text] [Related]
9. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice.
Xu X; Kreye E; Kuo CB; Walker AM
Cancer Res; 2001 Aug; 61(16):6098-104. PubMed ID: 11507059
[TBL] [Abstract][Full Text] [Related]
10. Internal image anti-idiotypic antibody: A new strategy for the development a new category of prolactin receptor (PRLR) antagonist.
Lan H; Hong P; Li R; L S; Anshan S; Li S; Zheng X
Mol Immunol; 2017 Jul; 87():86-93. PubMed ID: 28412548
[TBL] [Abstract][Full Text] [Related]
11. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
12. Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells.
Barcus CE; Holt EC; Keely PJ; Eliceiri KW; Schuler LA
PLoS One; 2015; 10(1):e0116891. PubMed ID: 25607819
[TBL] [Abstract][Full Text] [Related]
13. ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.
Cheal SM; Ruan S; Veach DR; Longo VA; Punzalan BJ; Wu J; Fung EK; Kelly MP; Kirshner JR; Giurleo JT; Ehrlich G; Han AQ; Thurston G; Olson WC; Zanzonico PB; Larson SM; Carrasquillo JA
Mol Pharm; 2018 Jun; 15(6):2133-2141. PubMed ID: 29684277
[TBL] [Abstract][Full Text] [Related]
14. Re-evaluation of the prolactin receptor expression in human breast cancer.
Galsgaard ED; Rasmussen BB; Folkesson CG; Rasmussen LM; Berchtold MW; Christensen L; Panina S
J Endocrinol; 2009 Apr; 201(1):115-28. PubMed ID: 19153125
[TBL] [Abstract][Full Text] [Related]
15. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer.
Zhou Y; Zong H; Han L; Xie Y; Jiang H; Gilly J; Zhang B; Lu H; Chen J; Sun R; Pan Z; Zhu J
J Exp Clin Cancer Res; 2020 May; 39(1):87. PubMed ID: 32398042
[TBL] [Abstract][Full Text] [Related]
16. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics.
Clevenger CV; Zheng J; Jablonski EM; Galbaugh TL; Fang F
J Mammary Gland Biol Neoplasia; 2008 Mar; 13(1):147-56. PubMed ID: 18246318
[TBL] [Abstract][Full Text] [Related]
17. The prolactin receptor as a therapeutic target in human diseases: browsing new potential indications.
Goffin V; Touraine P
Expert Opin Ther Targets; 2015; 19(9):1229-44. PubMed ID: 26063597
[TBL] [Abstract][Full Text] [Related]
18. The many faces of prolactin in breast cancer.
Chen WY
Adv Exp Med Biol; 2015; 846():61-81. PubMed ID: 25472534
[TBL] [Abstract][Full Text] [Related]
19. Alpha
Castillo LF; Rivero EM; Goffin V; Lüthy IA
Cell Signal; 2017 Jun; 34():76-85. PubMed ID: 28302567
[TBL] [Abstract][Full Text] [Related]
20. Development of a new anti-prolactin receptor (PRLR) antibody, F56, which can serve as a PRLR antagonist.
Cui H; Ma YZ; Wang Y; Song M; Zhang H
Int J Biol Macromol; 2017 Feb; 95():1223-1227. PubMed ID: 27829125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
